Molecular imaging probes for 31P contrast
<p><sup>31</sup>P magnetic resonance has yet to realise its clinical potential principally due to the relatively low sensitivity of the <sup>31</sup>P nucleus. While <sup>31</sup>P-MRS can uniquely provide vital information regarding in vivo phosphorus met...
Päätekijä: | Tear, L |
---|---|
Muut tekijät: | Faulkner, S |
Aineistotyyppi: | Opinnäyte |
Kieli: | English |
Julkaistu: |
2018
|
Aiheet: |
Samankaltaisia teoksia
-
Magnetic Resonance Imaging Contrast Agents: A Review of Literature
Tekijä: Zahra Sahraei, et al.
Julkaistu: (2015-10-01) -
Interval between contrast administration and T1-weighted MRI for cerebral adrenoleukodystrophy: a single-case observation
Tekijä: Marco Moscatelli, et al.
Julkaistu: (2023-10-01) -
Comparison of gadolinium-based contrast agents for MR cholangiography in saline, blood and bile: a phantom study
Tekijä: Johannes M. Froehlich, et al.
Julkaistu: (2023-04-01) -
Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to united states food and drug administration (FDA) guidelines
Tekijä: Nacif Marcelo S, et al.
Julkaistu: (2012-02-01) -
Toxicity associated with gadolinium-based contrast-enhanced examinations
Tekijä: Silvia Maria Lattanzio
Julkaistu: (2021-05-01)